Study wrapper · #961
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
Rao H, Kumar S, Ali SME, et al. Journal of diabetes and metabolic disorders. 2026.
DOI: 10.1007/s40200-026-01942-3PubMed: 42180166
Editor's note
This systematic review and meta-analysis pools four randomized trials to evaluate cagrilintide and CagriSema for weight management, reporting significant reductions in body weight and favorable cardiometabolic effects. Adverse events were more frequent with active treatment but discontinuation rates were comparable to placebo. As a synthesis of RCT data on tracked peptides it carries strong evidentiary weight, with effects framed as associations.
Plain-language abstract
A meta-analysis of four trials with over 5,000 participants found that cagrilintide and the cagrilintide-semaglutide combination were each associated with significant weight loss versus placebo, with more frequent but tolerable side effects.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026